RE: Finally ...I'm not sure how we can lean on MDT's due diligence? MDT hasn't taken any risk here? all payments are milestone which to me means that there isn't enough evidence for MDT to pay anything upfront. in other words they get a free first shot at a drug that might work, and if it does work, they pay for a license to it, and if it doesn't work they lose nothing. This agreement should move MDT's stock not RVX. MDT just added to their scientific portfolio without paying a dime?